ArticleCanadian liver journal2026
Evaluating the hepatitis C care cascade in Newfoundland and Labrador: Progress toward elimination.
Article in Canadian liver journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Care cascades are useful tools for tracking progress toward public health goals, including the World Health Organization's target of hepatitis C elimination by 2030. This study outlines the hepatitis C care cascade in Newfoundland and Labrador (NL) from 2018 to 2024 and assesses trends in access to testing and treatment. Methods: Provincial administrative health data on hepatitis C testing and treatment dispensing were analyzed. We calculated descriptive statistics for the full study period and compared two time intervals, with additional year-by-year analyses to examine trends. Results: From 2018 to 2024, the annual incidence of hepatitis C antibody positivity was 67.3 per 100,000 population. The diagnosis rate was 71%, and 25.6% of diagnosed individuals initiated treatment. Among those testing positive, the mean age was 40 years, 61% were male, and 31.5% were born between 1945 and 1975. Compared with 2018-2021, access to confirmatory RNA testing and treatment initiation improved in 2022-2024. Yearly trends showed steady increases in testing and treatment uptake, along with shorter time to treatment; by 2023, most individuals began treatment within 1 year of diagnosis. Conclusions: While access to testing and treatment improved over time, NL has not yet met hepatitis C elimination targets. Targeted interventions for higher-risk populations are needed to accelerate progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.